Although 3D printing for drugs and biologics still has ways to go to become common, the FDA and EMA have been receptive to proposal for products using this technology. As 3D printing (3DP) moves from rapid prototyping to the mass customization of solid oral dosage forms, regulatory frameworks are rapidly evolving to catch up with … Read more
The FDA’s transition to the Adverse Event Monitoring System (AEMS) represents a fundamental shift from fragmented legacy databases to a centralized, cross-center regulatory architecture. This modernization effort consolidates disparate reporting streams for drugs, biologics, and medical devices into a singular analytical interface designed to enhance signal detection and data accessibility. For industry leadership, this evolution … Read more
The FDA’s long-anticipated transition toward human-centric predictive toxicology has reached a pivotal milestone with the release of the March 2026 draft guidance on New Approach Methodologies (NAMs). This document provides the high-level validation framework necessary for sponsors to move away from legacy animal dependencies and toward scientifically robust, in vitro and in silico alternatives. For … Read more
The FDA’s recent release of two guidance documents for developing biosimilars signals a critical shift toward regulatory efficiency. For senior management and regulatory affairs leads, these documents clarify the Agency’s move to reduce redundant clinical testing and streamline the use of global comparator data. Understanding these nuances is essential for optimizing development timelines and capital … Read more
Following the issuance of a Form FDA 483, the window for regulatory advocacy is brief and high-stakes, necessitating a response that serves as a cornerstone for future enforcement decisions. While the industry has long relied on historical precedent and unofficial best practices, the March 2026 draft guidance finally formalizes the Agency’s expectations for post-inspection communication. … Read more
In pharmaceutical development, regulatory exclusivity can create a powerful competitive moat—often determining whether an innovative lifecycle strategy translates into meaningful market differentiation. The U.S. Food and Drug Administration (FDA) has released a draft guidance providing long-awaited clarity on the statutory and regulatory framework governing three-year exclusivity under the Hatch-Waxman Amendments. For regulatory affairs leaders, portfolio … Read more
Real-world data (RWD) has transitioned from an exploratory research asset to a strategic regulatory tool shaping post-market drug safety evaluations. As healthcare systems generate increasingly complex datasets, from electronic health records to insurance claims and disease registries, regulators are demanding more rigorous frameworks for translating these data into regulatory-grade evidence. The FDA’s adoption of the … Read more
For nearly a decade, basic scientists have wrestled with a classification that felt like a square peg in a round hole: the BESH designation. By labeling fundamental human behavior studies as “clinical trials,” the NIH sparked years of debate over administrative burden versus scientific transparency. Now, a massive policy shift is officially on the horizon, … Read more
The standard regulatory threshold of “substantial evidence of effectiveness” has historically relied on large-scale randomized controlled trials (RCTs) to mitigate statistical noise. For ultra-rare genetic conditions, however, the laws of small numbers make traditional RCTs practically and ethically unfeasible. The FDA’s latest guidance introduces a “Plausible Mechanism Framework” to bridge this gap, allowing deep molecular … Read more
Keeping pace with the rapid evolution of medical technology requires a regulatory framework that is both rigorous and agile. The FDA’s latest announcement regarding the Food and Drug Administration Modernization Act of 1997 represents a vital step in aligning regulatory expectations with modern engineering. By updating its list of recognized consensus standards, the agency is … Read more
